These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38348600)

  • 1. Cost-effectiveness analysis of vaccination strategies against meningococcal disease for children under nine years of age in China.
    Zhang H; Zhang H; Fang H
    Hum Vaccin Immunother; 2024 Dec; 20(1):2313872. PubMed ID: 38348600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary immunization of meningococcal meningitis vaccine among children in Hangzhou, China, 2008-2017.
    Che X; Liu Y; Wang J; Xu Y; Zhang X; Gu W; Jiang W; Du J; Zhang X
    Hum Vaccin Immunother; 2021 Apr; 17(4):1239-1243. PubMed ID: 32961071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
    Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
    Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
    De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
    Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children.
    Sow SO; Tapia MD; Haidara FC; Diallo F; Traore Y; Traoré A; Kodio M; Borrow R; Townsend-Payne K; Yuan L; Yang S; Shi L; Chen J; Fang G; Lin J; Hu R; Viviani S; Huang Z
    Hum Vaccin Immunother; 2023 Aug; 19(2):2230829. PubMed ID: 37401618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine.
    Watle SV; Næss LM; Tunheim G; Caugant DA; Wisløff T
    Hum Vaccin Immunother; 2021 Aug; 17(8):2777-2787. PubMed ID: 33631080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
    Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents.
    Si S; Zomer E; Fletcher S; Lee J; Liew D
    Vaccine; 2019 Aug; 37(35):5009-5015. PubMed ID: 31301916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study.
    Yaesoubi R; Trotter C; Colijn C; Yaesoubi M; Colombini A; Resch S; Kristiansen PA; LaForce FM; Cohen T
    PLoS Med; 2018 Jan; 15(1):e1002495. PubMed ID: 29364884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada.
    Delea TE; Weycker D; Atwood M; Neame D; Alvarez FP; Forget E; Langley JM; Chit A
    PLoS One; 2017; 12(5):e0175721. PubMed ID: 28472165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness Comparison of Monovalent C Versus Quadrivalent ACWY Meningococcal Conjugate Vaccination in Canada.
    De Wals P; Zhou Z
    Pediatr Infect Dis J; 2017 Jul; 36(7):e203-e207. PubMed ID: 28027288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
    Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
    Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of a single dose of the quadrivalent meningococcal conjugate vaccine, MenACWY-CRM, in the Korean Armed Forces.
    Im JH; Woo H; Ha BM; Lee JS; Chung MH; Jung J
    Vaccine; 2020 Jan; 38(4):730-732. PubMed ID: 31787413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
    Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
    BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.
    Dbaibo G; El-Ayoubi N; Ghanem S; Hajar F; Bianco V; Miller JM; Mesaros N
    Drugs Aging; 2013 May; 30(5):309-19. PubMed ID: 23494214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™).
    Croxtall JD; Dhillon S
    Drugs; 2012 Dec; 72(18):2407-30. PubMed ID: 23231026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of pneumococcal vaccines among adults aged 65 years and older in China: A comparative study.
    Guo J; Zhang H; Zhang H; Lai X; Wang J; Feng H; Fang H
    Vaccine; 2023 Jan; 41(3):716-723. PubMed ID: 36522264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands.
    Hepkema H; Pouwels KB; van der Ende A; Westra TA; Postma MJ
    PLoS One; 2013; 8(5):e65036. PubMed ID: 23741448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of routine immunization using meningococcal C conjugate vaccine on invasive meningococcal disease in British Columbia.
    Siu T; Tang W; Dawar M; Patrick DM
    Can J Public Health; 2008; 99(5):380-2. PubMed ID: 19009920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.
    Pouwels KB; Hak E; van der Ende A; Christensen H; van den Dobbelsteen GP; Postma MJ
    Hum Vaccin Immunother; 2013 May; 9(5):1129-38. PubMed ID: 23406816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.